Covered recipient · General Payments record
JENNIFER MCCART RICHARDSON
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2019–2025
$2,372.98
- Reported across 107 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $689.31 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $234.91 | 3 |
| Janssen Biotech, Inc. | $150.00 | 1 |
| UCB, Inc. | $115.09 | 2 |
| Amgen Inc. | $82.85 | 5 |
| GlaxoSmithKline, LLC. | $63.76 | 3 |
| Lilly USA, LLC | $21.63 | 1 |
| Biocon Biologics Inc | $21.07 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $21.63 | 02/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228587851 | CMS |
| Amgen Inc. | $15.72 | 06/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228587853 | CMS |
| Amgen Inc. | $16.45 | 07/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228587855 | CMS |
| Amgen Inc. | $15.13 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228587857 | CMS |
| Amgen Inc. | $13.92 | 11/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227102950 | CMS |
| Biocon Biologics Inc | $21.07 | 06/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1254658561 | CMS |
| GlaxoSmithKline, LLC. | $20.84 | 01/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190770318 | CMS |
| GlaxoSmithKline, LLC. | $21.64 | 04/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191736781 | CMS |
| GlaxoSmithKline, LLC. | $21.28 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191501264 | CMS |
| Janssen Biotech, Inc. | $150.00 | 12/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174335568 | CMS |
| Lilly USA, LLC | $21.63 | 01/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186723503 | CMS |
| Novartis Pharmaceuticals Corporation | $18.94 | 07/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200591273 | CMS |
| Novartis Pharmaceuticals Corporation | $72.66 | 10/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200591285 | CMS |
| Novartis Pharmaceuticals Corporation | $143.31 | 10/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200591283 | CMS |
| UCB, Inc. | $99.33 | 02/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224526334 | CMS |
| UCB, Inc. | $15.76 | 09/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224526336 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.